Recombinant human interferon-like proteins

Details Recombinant human interferon-like proteins Recombinant human interferon-like proteins

2007-06-18

2009-12-01

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C435S069510, C530S351000, C530S402000, C536S023520, C514S012200

Reexamination Certificate

active

07625555

ABSTRACT:
This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

REFERENCES:
patent: 3699222 (1972-10-01), Isaacs et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4885166 (1989-12-01), Meyer et al.
patent: 4914033 (1990-04-01), Bell et al.
patent: 5055289 (1991-10-01), Frincke et al.
patent: 5071761 (1991-12-01), Meyer et al.
patent: 5137720 (1992-08-01), Gangemi et al.
patent: 5605793 (1997-02-01), Stemmer
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 5908626 (1999-06-01), Chang et al.
patent: 6174708 (2001-01-01), Sodoyer et al.
patent: 6174996 (2001-01-01), Johnson et al.
patent: 6514729 (2003-02-01), Bentzien
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 6569420 (2003-05-01), Chen et al.
patent: 6685933 (2004-02-01), Zoon et al.
patent: 6946296 (2005-09-01), Patten et al.
patent: 7498152 (2009-03-01), Patten et al.
patent: 2003/0175241 (2003-09-01), Pedersen et al.
patent: 2004/0002474 (2004-01-01), Heinrichs et al.
patent: 2004/0013644 (2004-01-01), Rasmussen et al.
patent: 2004/0203118 (2004-10-01), Escary
patent: 2005/0201982 (2005-09-01), Hazel et al.
patent: 2005/0249703 (2005-11-01), Jensen
patent: 2006/0051859 (2006-03-01), Fu et al.
patent: 2007/0025966 (2007-02-01), Patten et al.
patent: 2007/0254838 (2007-11-01), Gantier et al.
patent: 1431018 (2003-07-01), None
patent: 0115736 (2001-03-01), None
patent: 0125438 (2001-04-01), None
patent: 0136001 (2001-05-01), None
patent: 0172993 (2001-10-01), None
patent: 0236627 (2002-05-01), None
patent: 0236628 (2002-05-01), None
patent: 02074806 (2002-09-01), None
patent: 02081507 (2002-10-01), None
patent: 03002152 (2003-01-01), None
patent: 03075944 (2003-09-01), None
patent: 2004005341 (2004-01-01), None
patent: 2004020468 (2004-03-01), None
patent: 2004046365 (2004-06-01), None
patent: 2005113592 (2005-12-01), None
Pr001305760, NCBI Probe DB (Applied Biosystems), Oct. 5, 2005, see 1305760c.1 RSA primer.
Interferon nomenclature. Nature. 1980; 286 (5769):110.
Jonasch E and Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001; 6(1):34-55.
Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem. 1982; 51:251-282.
Gresser I and Tovey MG. Antitumor effects of interferon. Biochim Biophys Acta. 1978; 516(2):231-247.
Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778-809.
Theofilopoulos AN, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005; 23:307-336.
Uze G, et al. Alpha and beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res. 1995; 15(1): 3-26.
Knight E Jr. Interferon: purification and initial characterization from human diploid cells. Proc Natl Acad Sci USA. 1976; 73(2):520-523.
Pestka S, et al. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004; 202:8-32.
Horisberger MA and Di Marco S. Interferon-alpha hybrids. Pharmacol Ther. 1995; 66(3):507-534.
Horton HM, et al. Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice. Cancer Res. 1999; 59(16):4064-4068.
Hardy MP, et al. Characterization of the type I interferon locus and identification of novel genes. Genomics.2004; 84 (2):331-345.
Pestka S, et al. Interleukin-10 and releated cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
Nardelli B, et al. Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J. Immunol. 2002; 169(9):4822-4830.
LaFleur DW, et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001; 276(43): 39765-39771.
Subramaniam PS, Johnson HM. The IFNAR1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence. FEBS Lett. 2004; 578(3):207-210.
Goodbourn S, et al. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol. 2000; 81(Pt 10):2341-2364.
Wang K, et al. Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signaling pathways. J Immunol. 2003; 171(2):1035-1041.
Katze MG. Interferon, PKR, virology, and genomics: what is past and what is next in the new millennium? J Interferon Cytokine Res. 2002; 22(3):283-286.
Chawla-Sarkar M, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003; 8(3):237-249.
Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002; 29(3 Suppl 7):18-26.
Hofmann V, et al. Hairy cell leukemia: an interferon deficient disease? Cancer Treat Rev. 1985; Suppl B: 33-37.
Stone RM , et al. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol. 1993; 16(2):159-163.
Talpaz M, et al. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med. 1983; 99(6):789-792.
Talpaz M, et al. Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients. Exp Hematol. 1986; 14(7):668-671.
Strander H, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. 1995; 34(6):877-880.
Dogan B, et al. Intralesional alfa-2a interferon therapy for basal cell carcinoma. Cancer Lett. 1995; 91(2):215-219.
FeteII MR, et al. Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study. Cancer. 1990; 65(1):78-83.
Muss HB. The use of interferon in renal cell carcinoma. Eur J Cancer. 1991; 27 (Suppl 4):S84-87.
Peest D, et al. Cytokine therapy in multiple myeloma. Br. J Haematol. 1996; 94(3):425-432.
lkic D, et al. Local interferon therapy for melanoma patients. Int. J Dermatol. 1995; 34(12):872-874.
Rybak ME, et al. Interferon therapy of relapsed and refractory Hodgkin's disease: Cancer and Leukemia Group B Study 8652. J Biol. Response Mod. 1990; 9(1):1-4.
Kaufmann R, et al. Temozolomide in combination with interferon-alpha versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005; 23(35):9001-9007.
Lane HC. The role of alpha-interferon in patients with human immunodeficiency virus infection. Semin Oncol. 1991; 18(Suppl 7):46-52.
Woo MH and Brunakis TG. Interferon alfa in the treatment of chronic viral hepatitis B and C. Ann. Pharmacother. 1997; 31(3):330-337.
Gibas AL. Use of interferon in the treatment of chronic viral hepatitis. Gastroenterologist. 1993; 1(2):129-142.
Levine LA, et al. Treatment of subclinical intraurethral human papilloma virus infection with interferon alfa-2b. Urology. 1996; 47(4):553-557.
Ho M. Interferon for the treatment of infections. Annu Rev Med. 1987; 38:51-59.
Wintergerst U and Belohradsky BH. Acyclovir monotherapy versus acyclovir plus beta-interferon in f

Affiliated with

Also associated with

Rating

Recombinant human interferon-like proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant human interferon-like proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human interferon-like proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4145488